This article was originally published in Start Up
Now that percutaneous coronary inverventions (PCIs) outnumber coronary bypass surgeries by nearly four to one, interventional cardiologists are spending significantly more time in the cath lab. Because PCIs are performed using radiological guidance, physicians must wear leaded garments to protect them from radiation exposure during lengthy procedures. The weight of these garments can lead to orthopedic back and joint problems over time. Corindus is addressing the occupational hazards that have accompanied PCI's growth with a remote control catheterization system that enables cardiologists to advance and manipulate interventional devices inside patients' arteries from a safe distance.
You may also be interested in...
A surprisingly large number of medical device start-ups emerge from Israel, and at the recent In3 (Investment in Innovation) conference sponsored by the Medtech Insight division of Windhover Information Inc. in Brussels, Belgium in late September, a distinguished panel of venture capitalists made sense of the country's unique climate for device innovation. The speakers also had some lessons to offer to fledgling European device companies as well. Taking part in the panel were Avi Molcho, MD, Managing Director, Life Sciences, for Giza Venture Capital, one of Israel's largest venture firms, Zeev Zehavi, VP of Johnson & Johnson Development Corp., responsible for J&J's corporate investments in Europe and Israel, and Yuval Binur, PhD, Chairman of the board of device company creator Accelerated Technologies.
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.